Vident Advisory, LLC

Position in ALNY — Alnylam Pharmaceuticals, Inc.

CIK 1744347 Alpharetta, GA

Position in ALNY

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$1,661,083

-$475,343 QoQ

Shares Held

5,518

-14.5% QoQ

Ownership

0.004%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#348

of 786 holders

Holding Since

Sep 2023

12 quarters on record

Voting authority Sole 99% Shared 0% None 1%

Healthcare · as of Jun 30, 2026

Vident Advisory, LLC holds $52,891,507 across 43 Biotechnology names. ALNY ranks #7 (3.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	EXEL	Exelixis, Inc.	148,975	$8,105,728
2	JAZZ	Jazz Pharmaceuticals plc	28,409	$6,845,716
3	VRTX	Vertex Pharmaceuticals Inc / Ma	12,522	$6,220,051
4	REGN	Regeneron Pharmaceuticals, Inc.	7,804	$4,866,104
5	RVMD	Revolution Medicines, Inc.	13,776	$2,579,967
6	LGND	Ligand Pharmaceuticals Inc	6,151	$1,944,268
7	ALNY	Alnylam Pharmaceuticals, Inc. This page	5,518	$1,661,083
8	CYTK	Cytokinetics Inc	15,898	$1,354,349

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,661,083	5,518	-14.5%	Shares	Defined	2026-08-12
2026-03-31	$2,136,426	6,457	+25.3%	Shares	Sole	2026-05-15
2025-12-31	$2,049,885	5,155	-1.6%	Shares	Defined	2026-02-18
2025-09-30	$2,388,072	5,237	+33.4%	Shares	Defined	2025-11-14
2025-06-30	$1,279,902	3,925	+47.2%	Shares	Sole	2025-08-14
2025-03-31	$720,143	2,667	+101.0%	Shares	Defined	2025-05-15
2024-12-31	$312,255	1,327	+21.2%	Shares	Defined	2025-02-14
2024-09-30	$301,157	1,095	-37.4%	Shares	Sole	2024-11-14
2024-06-30	$425,007	1,749	+12.0%	Shares	Sole	2024-08-14
2024-03-31	$233,290	1,561	-16.5%	Shares	Defined	2024-05-14
2023-12-31	$357,744	1,869	+7.1%	Shares	Sole	2024-02-14
2023-09-30	$309,038	1,745	—	Shares	Defined	2024-02-21
No filing history on record for this holder in this stock.